Chris Macaraeg

Amgen (United States)

Papers

1

Total Citations

11

H-Index

1

About

Chris Macaraeg is a researcher whose work bridges bioanalytical chemistry and macromolecular drug development. His key contributions center on advancing electrochemiluminescence (ECL) detection platforms for regulated bioanalysis, particularly for large-molecule therapeutics. His most-cited paper, "Applications of a planar electrochemiluminescence platform to support regulated studies of macromolecules: Benefits and limitations in assay range" (2009, 11 citations), critically evaluates the practical utility of planar ECL technology in supporting pharmacokinetic and immunogenicity studies. This work highlights both the strengths—such as high sensitivity and throughput—and the constraints of assay dynamic range, providing essential guidance for method validation in regulated environments. Macaraeg’s research has directly informed the design of robust bioanalytical strategies for monoclonal antibodies and other biologics, helping to ensure data integrity in drug development pipelines. While his citation count reflects a focused, niche impact, his work remains a reference point for scientists navigating the trade-offs between platform capabilities and regulatory expectations. His contributions underscore the importance of method characterization in translating novel detection technologies from research to routine application.

Research Focus

Key Achievements

1
H-Index
1
Papers
11
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Applications of a planar electrochemiluminescence platform to support regulated studies of macromolecules: Benefits and limitations in assay range
11 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Amgen (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago